A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial - PubMed

7 hours ago

A phase 1 trial of a structure-based mRNA vaccine (mRNA-1215) for Nipah virus (NiV) was conducted in healthy adults.
The vaccine encodes a chimeric pre-fusion F (Pre-F) protein linked to glycoprotein G of a NiV Malaysian strain.
Forty participants were enrolled into four dose groups (10, 25, 50, or 100 μg) and received two doses intramuscularly at a 4-week interval.
The vaccine demonstrated a favorable safety profile, with mild pain and tenderness at the injection site (82%) and mild malaise (40%) as the most common adverse events.
No serious adverse events occurred during the study.
mRNA-1215 elicited robust Pre-F and G binding antibody titers and neutralizing titers by 2 weeks after the first dose, with responses increasing after the booster dose.
Immune responses remained elevated for at least 1 year after vaccination.
The vaccine is a promising candidate for further clinical development for populations at risk for Nipah virus outbreaks.

Hasty Briefsbeta